Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 9Genitourinary 2Gastrointestinal 2Thoracic 1Plasma cell 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Brain Neoplasms 274Glioblastoma 251Glioma 190Neuroblastoma 84Neoplasms 59Central Nervous System Neoplasms 55Astrocytoma 54Medulloblastoma 46Breast Neoplasms 43Melanoma 39Sarcoma 38Neurofibromatosis 1 37Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 36Meningioma 35Ependymoma 35Osteosarcoma 29Rhabdomyosarcoma 28Diffuse Intrinsic Pontine Glioma 28Recurrence 27Sarcoma, Ewing 26Neoplasm Metastasis 26Rhabdoid Tumor 25Oligodendroglioma 23Wilms Tumor 21Gliosarcoma 21Pancreatic Neoplasms 20Pheochromocytoma 19Hepatoblastoma 19Thyroid Neoplasms 18

Interventions

cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × CNS × 90 days × Clear all
NCT02867592 2026-06-11

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡